First study to suggest that the immune system may protect against Alzheimer’s changes in humans
- May 25, 2012
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer’s-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.
Researchers at the Peninsula College of Medicine and Dentistry, University of Exeter with colleagues in the National Institute on Aging in the USA and in Italy screened the expression levels of thousands of genes in blood samples from nearly 700 people. The telltale marker of immune system activity against beta-amyloid, a gene called CCR2, emerged as the top marker associated with memory in people.
The team used a common clinical measure called the Mini Mental State Examination to measure memory and other cognitive functions.
The previous work in mice showed that augmenting the CCR2-activated part of the immune system in the blood stream resulted in improved memory and functioning in mice susceptible to Alzheimer’s disease.
Professor David Melzer, who led the work, commented: “This is a very exciting result. It may be that CCR2-associated immunity could be strengthened in humans to slow Alzheimer’s disease, but much more work will be needed to ensure that this approach is safe and effective”.
Dr Lorna Harries, co-author, commented: “Identification of a key player in the interface between immune function and cognitive ability may help us to gain a better understanding of the disease processes involved in Alzheimer’s disease and related disorders.”
Alzheimer’s disease is the most common form of dementia and affects around 496,000 people in the UK.
Note to Editors
The Peninsula College of Medicine and Dentistry is a joint entity of the University of Exeter, Plymouth University and the NHS in the South West of England. PCMD has created for itself an excellent national and international reputation for groundbreaking research in the areas of diabetes and obesity, neurological disease, child development and ageing, dentistry, clinical education and health technology assessment.
Lorna W. Harries, Rachel M. Bradley-Smith, David J. Llewellyn, Luke C. Pilling, Alexander Fellows, William Henley, Dena Hernandez, Jack M. Guralnik, Stefania Bandinelli, Andrew Singleton, Luigi Ferrucci and David Melzer.
The previously published research in mice from a team in Canada is:
Naert G, Rivest S. Hematopoietic CC-chemokine receptor 2-(CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s disease.
Also in this section
- Molecular trigger for Alzheimer’s disease identified
- Study finds that sleep apnea and Alzheimer’s are linked
- APA Leaders Defend New Diagnostic Guide
- One million Dementia Friends will help make life better for people with dementia
- Expressions of interest for funding to improve care environments for people with dementia
- Dementia Facts And Statistics: Present And Future
- Cancer drug prevents build-up of toxic brain protein
- Could eating peppers prevent Parkinson’s?
- Promising Alzheimer’s Drug Fails in Study
- No link between anesthesia, dementia in elderly, Mayo Clinic Study finds
- Mild blast injury causes molecular changes in brain akin to Alzheimer, Pitt team says
- Swedish study suggests reduced risk of dementia
Post a comment [ + Comment here + ]
There are no comments for this entry yet. [ + Comment here + ]
Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.